Cardiosense

Company profile

About Cardiosense

Cardiosense is a medical technology company that leverages wearable sensing technology, advanced signal processing, and deep learning to transform physiological data into actionable clinical insight for cardiovascular disease management. The company's flagship product, which recently received FDA De Novo approval, is the first and only heart failure monitoring solution to determine Pulmonary Capillary Wedge Pressure (PCWP) noninvasively at point-of-care. The CardioTag wireless sensor and PCWP Analysis Software enable clinicians to more precisely and proactively manage heart failure patients across all care settings—from emergency departments and inpatient facilities to outpatient clinics and home monitoring. By providing quantitative PCWP readings in minutes, Cardiosense enables early detection and intervention weeks before fluid builds up and symptoms arise, helping reduce heart failure hospitalizations and improve long-term patient outcomes. The technology is validated against right heart catheterization with accuracy on par with implantable sensors, offering a rapid, easy-to-use alternative that eliminates guesswork in heart failure management. Founded by engineers and scientists, Cardiosense's AI platform addresses complex cardiovascular challenges by converting raw physiological data into clinical intelligence, providing both clinicians and patients with tools for precise, proactive disease management.

Company description · Cardiosense official website